Dapagliflozin, an SGLT-2 inhibitor, is being evaluated for its impact on pulmonary artery hemodynamics in patients with heart failure with reduced ejection fraction (HFrEF) who have the CardioMEMS device implanted. This study aims to expand the therapeutic use of dapagliflozin beyond its current FDA-approved indications for HFrEF and diabetes, potentially enhancing its market position in the heart failure treatment landscape. The growing prevalence of heart failure and the increasing adoption of remote monitoring technologies like CardioMEMS present significant market opportunities. Competitive implications include the need to monitor other SGLT-2 inhibitors and their respective clinical trials targeting similar patient populations.